One radical is briefly caged on the nickel, allowing it to snap back before it can escape.
At the intersection of molecular geometry and chemical ingenuity, chemists at Scripps Research have found a way to join complex three-dimensional molecular fragments without erasing the precise handedness that gives medicines their power. Published in Science in June 2026, the method uses reactive free radicals guided by a nickel catalyst to preserve the spatial identity of molecules during bond formation — a challenge that has frustrated pharmaceutical synthesis for generations. The discovery matters because the shape of a drug molecule is not merely aesthetic; it is the difference between healing and harm, between a key that opens a lock and one that jams it.
- For decades, preserving a molecule's three-dimensional chirality while forming new carbon-carbon bonds has forced chemists into slow, wasteful, multi-step detours — a bottleneck costing the pharmaceutical industry enormous time and resources.
- Free radicals, among the most unstable species in chemistry, normally lose their spatial orientation almost instantly, making stereoretentive coupling feel like trying to hand-deliver a message using lightning.
- The Scripps team's 'caged radical rebound' mechanism briefly shelters one radical on a nickel catalyst, giving it just enough protection to snap into a new bond before its handedness can dissolve — achieving 80 to 96 percent enantiospecificity.
- A synthesis that once demanded seven steps and a costly separation of mirror-image forms can now be completed in a single step with 60 percent yield and 95 percent stereoretention, a compression of effort that reverberates across drug development timelines.
- Paired with AI-driven route planning, the method points toward a future where assembling complex 3D pharmaceutical architectures becomes as routine and reliable as the aryl coupling reactions chemists have trusted for years.
Chemists at Scripps Research have cracked a problem central to pharmaceutical synthesis: joining two complex molecular pieces while preserving their three-dimensional shape. The breakthrough, published in Science on June 4, 2026, harnesses reactive free radicals and a nickel catalyst to accomplish what was long considered nearly impossible.
The difficulty runs deep. Most drugs work because their molecules possess a specific spatial "handedness" — chirality — that lets them fit biological targets the way a left hand fits a left glove. The mirror image of the same molecule may do nothing useful, or worse, cause harm. Yet radicals, by nature, lose their orientation almost instantly, making stereoretentive coupling extraordinarily difficult. Traditional routes demand many steps, expensive reagents, or slow workarounds.
The Scripps team, led by Phil Baran, sidesteps these obstacles by letting chemists couple two pre-assembled fragments directly. A sulfonyl hydrazide and an alkyl halide each generate short-lived carbon radicals, but the nickel catalyst briefly "cages" one radical in a protected environment — long enough for it to rebound and form a new bond before its handedness is lost. The result is 80 to 96 percent enantiospecificity under standard laboratory conditions, with no need for special additives or shape-directing molecules.
The practical gains are dramatic. A piperidine building block that once required seven synthesis steps can now be made in one, with 60 percent yield and 95 percent stereoretention. The team also synthesized stenusine — a natural compound beetles use to glide across water — in fewer steps than any prior method. The reaction scales to gram quantities and can even link two secondary radicals to create molecules with adjacent chiral centers.
Baran sees the method as a structural shift in how chemists think. By making stereoretentive alkyl-alkyl coupling as routine as established aryl reactions, it could shorten synthetic routes, cut chemical waste, and open vast new regions of chemical space to exploration. Combined with AI-driven synthesis planning, the approach carries the potential to fundamentally reshape how the pharmaceutical industry designs and builds the medicines of the future.
Chemists at Scripps Research have solved a problem that has vexed pharmaceutical synthesis for decades: how to snap two complex molecular pieces together while keeping their three-dimensional shapes exactly as they were. The breakthrough, published in Science on June 4, 2026, uses reactive free radicals—some of the most unstable molecules in chemistry—and a simple nickel catalyst to accomplish what was previously thought nearly impossible.
The challenge is fundamental to drug design. Most medicines work because their molecules have a specific three-dimensional "handedness," or chirality, that allows them to fit into biological targets the way a left hand fits into a left glove. The mirror-image version of the same molecule often does nothing at all, or worse, it binds differently and causes unwanted side effects. Yet creating and preserving this precise three-dimensional arrangement while linking carbon atoms has been notoriously difficult, especially when working with highly reactive radicals that normally lose their orientation almost instantly. Traditional approaches require many synthetic steps, expensive catalysts, or force chemists to build molecules in a slower, less efficient manner.
The Scripps team's method, led by senior author Phil Baran, bypasses these limitations by allowing chemists to take two pre-assembled, complex molecular fragments and join them directly. The reaction couples a sulfonyl hydrazide—a compound that already carries the desired three-dimensional information—with a common organic molecule called an alkyl halide. Both generate short-lived carbon radicals, but the nickel catalyst orchestrates their encounter with precision. One radical is briefly "caged" on the nickel in a protected environment, allowing it to snap back and form the new bond before it can escape and lose its handedness. This "caged radical rebound" is the key to preserving the three-dimensional arrangement while maintaining 80 to 96 percent enantiospecificity—meaning the product usually keeps its starting handedness.
What makes this approach particularly elegant is its simplicity. The process is redox-neutral, so there's no need for extra chemicals to drive the reaction forward. It doesn't require specialized additives or shape-directing helper molecules, and it runs under standard laboratory conditions. The method tolerates the kinds of chemical parts that drug chemists rely on to build and fine-tune medicines—including free amines, olefins, heterocycles, and aryl bromides—without triggering unwanted side reactions. The team tested roughly one thousand conditions before arriving at the optimized protocol, then demonstrated it on dozens of starting materials, focusing on piperidine and pyrrolidine scaffolds, chemical structures commonly found in pharmaceuticals.
The practical impact is striking. A medicinally relevant piperidine building block that previously required seven steps to synthesize—including a separate step to isolate the molecule's left- and right-handed forms—can now be prepared in a single coupling step with 60 percent yield and 95 percent stereoretention. The researchers also used the method to build stenusine, a natural product that certain beetles excrete from their feet to glide across water, using fewer steps than previous techniques. The reaction scales to gram quantities and can even couple two secondary radicals to create molecules with adjacent chiral centers.
Baran frames the significance in terms of how chemists approach their work from the ground up. By making stereoretentive alkyl-alkyl bond formation as straightforward as many aryl couplings—well-established reactions that have been routine for years—the method could shorten synthetic routes, reduce chemical waste, and accelerate the exploration of chemical space. When paired with artificial intelligence to map out new routes for creating drugs, the potential to reshape pharmaceutical chemistry workflows becomes clear. The work extends Baran's earlier advances in radical-based cross-coupling, which have already begun changing how industry designs molecules. For a field where efficiency and precision are measured in years of development time and billions of dollars, a method that simplifies how complex structures are assembled changes everything.
Citas Notables
Our approach lets us connect the most reactive pieces and still get precise results.— Phil Baran, Scripps Research
If we can simplify how those structures are assembled, it changes how chemists approach synthesis from the ground up.— Phil Baran, Scripps Research
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this reaction preserves the three-dimensional shape? Can't chemists just make both versions and pick the right one?
They can, but it's wasteful and expensive. If you have to make both the left-handed and right-handed versions and then separate them—which takes extra steps and chemicals—you're throwing away half your product. This method lets you build the correct shape from the start.
You mentioned "caged radical rebound." That sounds like the radical is being held in place. How does that actually work?
The nickel atom acts like a temporary cage. One of the reactive radicals lands on the nickel and stays there just long enough for the other radical to arrive and bond with it. Before the caged radical can escape and lose its orientation, it snaps back to form the new bond. It's about timing and protection.
The article mentions this reduces some syntheses from seven steps to one. Is that realistic, or is that a cherry-picked example?
It's real, but it's the best-case scenario. The team tested roughly a thousand conditions to get there. Most reactions probably see a reduction of two or three steps, which is still significant in drug chemistry. But yes, that seven-to-one example shows what's possible when the method works optimally.
What happens to all the other molecules that don't fit this pattern? Does this replace older methods?
No, it's a new tool in the toolbox. Some molecules will still need the old approaches. But for the kinds of structures that do fit—and those include many common pharmaceutical scaffolds—this becomes the faster route. Over time, as chemists get more familiar with it, it might become the default choice for those molecules.
You said it tolerates free amines and other functional groups without side reactions. Why is that unusual?
Reactive radicals are promiscuous. They'll attack almost anything nearby. Most radical reactions require you to protect those other functional groups first, then remove the protection later. That's extra steps. This nickel catalyst is selective enough that those groups can stay exposed and unharmed.